The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•14 May 2026•

2 min read

BridgeBio Pharma Submits FDA Application for ADH1 Therapy Encaleret

Key Facts

1BridgeBio Pharma submitted a New Drug Application (NDA) to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1).

2The drug demonstrated rapid and sustained normalization of calcium metabolism in Phase 3 trial results.

BridgeBio Pharma has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for encaleret, an investigational therapy for autosomal dominant hypocalcemia type 1 (ADH1). The submission is based on positive Phase 3 clinical trial data which demonstrated the drug's ability to achieve rapid and sustained normalization of calcium metabolism. According to reports, encaleret aims to become the first approved therapy for this rare genetic disorder, supported by a favorable safety profile.

This regulatory milestone places BridgeBio at the forefront of the rare disease market, competing alongside peers such as Amicus Therapeutics and Kyowa Kirin. Compared to previous quarters, this filing significantly de-risks the company's late-stage pipeline; analysts at JPMorgan recently noted in research citations that a successful launch could address a market opportunity exceeding $1 billion annually. Per market data, the investment community is now awaiting the FDA's formal acceptance of the filing, typically expected within a 60-day window.

Investors are closely monitoring BBIO stock performance following the announcement, focusing on the upcoming FDA validation of the application. While the economic calendar shows broader market catalysts like U.S. Initial Jobless Claims on May 14, 2026 (per market data), the primary driver for the stock remains the assignment of a PDUFA action date. Market participants should watch for any supplemental data releases or regulatory feedback that could impact the approval timeline for this first-in-class therapy.